Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Alx Oncology Holdings (ALXO) Equity Average (2019 - 2026)

Alx Oncology Holdings' Equity Average history spans 5 years, with the latest figure at $179.2 million for Q4 2023.

  • On a quarterly basis, Equity Average fell 34.88% to $179.2 million in Q4 2023 year-over-year; TTM through Dec 2023 was $179.2 million, a 34.88% decrease, with the full-year FY2023 number at $226.6 million, down 27.67% from a year prior.
  • Equity Average hit $179.2 million in Q4 2023 for Alx Oncology Holdings, down from $190.7 million in the prior quarter.
  • Over the last five years, Equity Average for ALXO hit a ceiling of $424.2 million in Q1 2021 and a floor of -$80.2 million in Q2 2020.
  • Historically, Equity Average has averaged $214.3 million across 5 years, with a median of $263.6 million in 2022.
  • Biggest five-year swings in Equity Average: surged 678.81% in 2021 and later crashed 36.77% in 2023.
  • Tracing ALXO's Equity Average over 5 years: stood at -$66.8 million in 2019, then skyrocketed by 610.32% to $340.9 million in 2020, then grew by 9.73% to $374.1 million in 2021, then fell by 26.44% to $275.2 million in 2022, then plummeted by 34.88% to $179.2 million in 2023.
  • Business Quant data shows Equity Average for ALXO at $179.2 million in Q4 2023, $190.7 million in Q3 2023, and $226.5 million in Q2 2023.